Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double‐blind, placebo‐controlled trial
Pere Ginés, Antoni Rimola, Ramón Planas, Victor Vargas, Francesc Marco, Manuel Almela, Montserrat Forne, Maria Luisa Miranda, Josep Llach, Joan Manuel Salmerón, Maria Esteve, Josep Maria Marques, Maria Teresa Jiménez de Anta, Vicente Arroyo, Joan Rodés – 1 October 1990 – Eighty cirrhotic patients who had recovered from an episode of spontaneous bacterial peritonitis were included in a multicenter, double‐blind trial aimed at comparing long‐term norfloxacin administration (400 mg/day; 40 patients) vs. placebo (40 patients) in the prevention of spontaneous bacterial peritonitis recurrence.